The use of combination regimens with BRAF and MEK inhibitors has contributed to modify the prognosis of patients with BRAF V600 mutated melanomas and preclinical and clinical evidences actually available, suggest that the long term efficacy of these therapies could be attributed in part to an immune-modulating effect [16]. The gene discussed is MAP2K7; the disease is melanoma.